Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

This study tests a drug called iberdomide (alone or with a low-dose steroid called dexamethasone) for people with smoldering multiple myeloma (SMM) — a pre-cancer blood condition that hasn't yet caused symptoms but is at intermediate or high risk of progressing to full myeloma. The goal is to see if early treatment can delay or prevent progression. **You may be eligible if...** - You have been diagnosed with intermediate- or high-risk smoldering multiple myeloma within the past 5 years - Your blood or bone marrow shows specific markers of higher risk (e.g., many plasma cells in the bone marrow, abnormal protein levels) - You are in reasonable physical condition (ECOG 0–2) - Your blood counts are adequate **You may NOT be eligible if...** - You already have active (symptomatic) multiple myeloma - You were diagnosed with SMM more than 5 years ago - You have had prior treatment for myeloma - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.